HER2/low breast cancers are usually hormone receptor positive (HR+) and make up the majority of breast cancers (65–83%), while the rest are HR/negative and show a predominance of triple-negative breast cancers (TN-BC) [10, 11]. This evidence concerns the gene ERBB2 and breast cancer.